HSV1/HSV2 Specific Neutra™ Antibody Products

Are you struggling with prolonged HSV drug development timelines or encountering viral resistance in neutralizing antibody development? Creative Biolabs' HSV1/HSV2 specific Neutra™ antibody products overcome these barriers using advanced protein engineering and phage display platforms, enabling rapid generation of high-affinity antibodies for robust virological research and therapeutic discovery.

Introduction to HSV1/HSV2

Herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) are neurotropic DNA viruses of the Herpesviridae family. Globally, HSV1 infects 67% of individuals under 50, primarily causing orolabial lesions, while HSV2 affects 13% of adults worldwide, predominantly linked to genital ulcers. Both establish lifelong latent infections in sensory ganglia, reactivating under stress or immunosuppression.

• Structure

HSV virions comprise an icosahedral capsid surrounded by a tegument layer and lipid envelope. Key envelope glycoproteins (gB, gC, gD, gH/gL) mediate host cell entry: gD binds to nectin-1 or HVEM receptors, triggering membrane fusion via gB and gH/gL. This multi-step entry mechanism offers critical epitopes for neutralizing antibodies.

Fig.1 The HSV1/HSV2 structure.¹

• Related Signaling Pathways

HSV infection disrupts host antiviral responses by modulating:

- Interferon (IFN) pathways: HSV1 ICP34.5 protein inhibits TBK1-IRF3 signaling to evade innate immunity.

- NF-κB activation: Tegument protein VP16 promotes viral gene transcription while suppressing pro-inflammatory cytokine release.

- PI3K/Akt survival pathway: Viral glycoproteins enhance host cell survival to prolong replication cycles.

• Associated Pathologies

HSV1 causes recurrent oral ulcers, keratitis, and encephalitis, while HSV2 drives genital lesions, neonatal herpes, and meningitis. Over 80% of primary HSV infections are asymptomatic but facilitate silent transmission. Reactivation in immunocompromised individuals heightens risks of severe complications, including disseminated infections.

Applications of Anti-HSV1/HSV2 Neutralizing Antibodies

• Therapeutic Intervention

Neutralizing antibodies reduce viral load in acute HSV episodes and suppress reactivation in preclinical models. Early administration in immunocompromised patients correlates with improved clinical outcomes by lowering mucosal shedding and lesion severity.

• Diagnostic Development

High-specificity antibodies enable rapid HSV antigen detection in swab or serum samples, enhancing diagnostic accuracy for early infection. Quantitative ELISAs using these reagents differentiate HSV1/HSV2 seropositivity, aiding epidemiological surveillance.

• Prophylactic Strategy

Passive immunization with neutralizing antibodies protects high-risk populations (e.g., neonates, transplant recipients) from primary infection. Preclinical data demonstrate >75% efficacy in blocking genital HSV2 transmission in murine models.

• Vaccine Research

Antibodies isolated from convalescent sera guide epitope-focused vaccine design. gD and gB neutralizing titers serve as key correlates of protection in vaccine efficacy trials.

Our Anti-HSV1/HSV2 Neutralizing Antibody Products

Creative Biolabs' antibodies specifically target conformational epitopes on viral glycoproteins to block entry or cell-to-cell spread:

- gD-specific antibodies: Prevent receptor binding, neutralizing >90% of free virions in vitro.

- gB-directed clones: Inhibit post-attachment fusion steps, synergistic with gD-neutralizing agents.

- Cross-reactive antibodies: Bind conserved gB/gH domains shared between HSV1 and HSV2, offering broad protection.

Validated in ELISA, flow cytometry, and pseudovirus assays, these antibodies support mechanistic virology studies, therapeutic candidate screening, and diagnostic assay development.

Creative Biolabs delivers rigorously validated HSV1/HSV2 specific Neutra™ antibodies to address virological challenges across research, diagnostics, and therapeutics. Our team can tailor these solutions for neutralizing antibody development, epitope mapping, and functional assay design.

Contact our experts today to discuss custom projects or request product portfolios.

REFERENCE

1. Draganova, Elizabeth B., Jonathan Valentin, and Ekaterina E. Heldwein. "The ins and outs of herpesviral capsids: divergent structures and assembly mechanisms across the three subfamilies." Viruses 13.10 (2021): 1913. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3390/v13101913